US FDA task force to weigh disclosure of complete response letters
07 October 2009
Sue Sutter
The US
FDA's transparency task force will hear comments on whether the agency should publicly communicate decisions about pending drug product applications during a November 3rd public meeting. Commenters are asked to discuss whether the agency should disclose receipt of NDAs and BLAs, as well as non-approval...
Please Login to read the full article.
07 October 2009
Sue Sutter
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Obama pushes for crowdfunding, while SEC panel cautious
- US Capitol Capsule: Obama expects more 'nickel and diming' of health reform
- US Capitol Capsule: New York Democratic win exposes vulnerability of tampering with Medicare
- US Capitol Capsule: Could another biosimilars fight be a brewin'?
COMMENT
Other Informa Comment
FEATURES
- Merck BioVentures: where biosimilars make a difference
- Chinese producers may be losing price edge to India, says Granules MD
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
